Samsung Biologics to provide fill-finish manufacturing for Moderna’s COVID-19 vaccine Samsung Biologics will provide large-scale fill-finish manufacturing for Moderna’s COVID-19 vaccine from its facilities in South Korea. Upon execution of the deal, technology transfer will commence immediately. Samsung Biologics’ Incheon facilities will use a state-of-the-art production line equipped for aseptic fill-finish, labeling, and packaging services. The agreement will support the production of hundreds of millions of doses of Moderna’s COVID-19 vaccine, destined to supply of markets outside of the US. John Rim, CEO of Samsung Biologics, said: “Due to the high level of urgency in supplying the vaccine to the global population, we have set immediate action plans and schedule to make mRNA-1273 available for commercial distribution in the early second half of 2021.”